Summary
Background
This non-therapeutic biosimilar antibody utilizes the same variable regions as the therapeutic antibody Glembatumumab, making it ideal for research use. Glembatumumab is a fully human IgG2 monoclonal antibody that targets glycoprotein non-metastatic melanoma protein B (GPNMB), a transmembrane glycoprotein overexpressed in various cancers, including triple-negative breast cancer (TNBC), melanoma, glioblastoma, and osteosarcoma. GPNMB is associated with tumor progression, metastasis, and poor prognosis. In therapeutic applications, Glembatumumab is conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) to form the antibody-drug conjugate (ADC) Glembatumumab vedotin. This ADC binds to GPNMB-expressing tumor cells, is internalized, and releases MMAE intracellularly, leading to cell death. However, this biosimilar is unconjugated and formulated for non-therapeutic research use only, making it an excellent tool for studying GPNMB biology, tumor immunology, and the development of GPNMB-targeted therapies.
